JAK Mutations May Identify Patients Unlikely to Respond to Keytruda, Other PD-1 Blockers
News
The anti-PD-1 agent Keytruda (pembrolizumab) is unlikely to benefit patients whose cancers have mutations in the JAK1 or JAK2 genes, according to a recent UCLA study showing that such mutations lead ... Read more